Finding suitable biomarkers for patients with inflammatory bowel disease (IBD), either Crohn’s disease or ulcerative colitis, can be challenging.
But by identifying and targeting biomarkers, clinicians can target earlier interventions and treatments that ultimately could result in better care.
In data presented during the 2021 American College of Gastroenterology (ACG) Annual Meeting, a team led by Marla C. Dubinsky, MD, Professor of Pediatrics, Icahn School of Medicine at Mount Sinai, found patients with the absence of urgency had significantly greater reductions in levels of inflammatory biomarkers C-reactive protein (CRP) and fecal calprotectin (fCLP) in a cohort of patients treated with mirikizumab.